Increased reactive oxygen species production, impaired endothelial nitric oxide synthase activity and endothelial dysfunction were observed in LOX-1TG mice as compared with WT littermates. LOX-1 ...
European Heart Journal, Akhmedov, Alexander, Rozenberg, Izabela, Paneni, Francesco, Camici, Giovanni G., Shi, Yi, Doerries, Carola, Sledzinska, Anna, Mocharla, Pavani, Breitenstein, Alexander, ...
Increased reactive oxygen species production, impaired endothelial nitric oxide synthase activity and endothelial dysfunction were observed in LOX-1TG mice as compared with WT littermates. LOX-1 ...
European Heart Journal, Akhmedov, Alexander, Rozenberg, Izabela, Paneni, Francesco, Camici, Giovanni G., Shi, Yi, Doerries, Carola, Sledzinska, Anna, Mocharla, Pavani, Breitenstein, Alexander, ...
Abstract Aims The mammalian silent information regulator-two 1 (Sirt1) blunts the noxious effects of cardiovascular risk factors such as type 2 diabetes mellitus and obesity. In vivo, mice treated ...
Cardiovascular Research, Breitenstein, Alexander, Stein, Sokrates, Holy, Erik W., Camici, Giovanni G., Lohmann, Christine, Akhmedov, Alexander, Spescha, Remo, Elliott, Peter J., Westphal, Christoph ...
Abstract Aims The mammalian silent information regulator-two 1 (Sirt1) blunts the noxious effects of cardiovascular risk factors such as type 2 diabetes mellitus and obesity. In vivo, mice treated ...
Cardiovascular Research, Breitenstein, Alexander, Stein, Sokrates, Holy, Erik W., Camici, Giovanni G., Lohmann, Christine, Akhmedov, Alexander, Spescha, Remo, Elliott, Peter J., Westphal, Christoph ...
[...]the effect of mTOR inhibition on TF activity and thrombus formation in vivo has not yet been studied. [...]it is unclear whether second-generation DES substances everolimus and zotarolimus have ...
European Heart Journal, Camici, Giovanni G., Steffel, Jan, Amanovic, Ilijana, Breitenstein, Alexander, Baldinger, Janette, Keller, Stephan, Lüscher, Thomas F., Tanner, Felix C.
[...]the effect of mTOR inhibition on TF activity and thrombus formation in vivo has not yet been studied. [...]it is unclear whether second-generation DES substances everolimus and zotarolimus have ...
European Heart Journal, Camici, Giovanni G., Steffel, Jan, Amanovic, Ilijana, Breitenstein, Alexander, Baldinger, Janette, Keller, Stephan, Lüscher, Thomas F., Tanner, Felix C.